Needham & Company Q2 Preview on Cubist Pharmaceuticals (CBST); Cubicin Sales Estimate is $195M
Go back to Needham & Company Q2 Preview on Cubist Pharmaceuticals (CBST); Cubicin Sales Estimate is $195M| Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) | Delayed: 101.94 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $101.94 | 52 Week High | $101.99 | |||
| Open | $3.23 | 52 Week Low | $58.50 | |||
| Day High | $101.94 | P/E | N/A | |||
| Day Low | $101.94 | EPS | $-0.27 | |||
| Volume | 3,714 | |||||
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1180.16 -27.11 (2.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1207.27 | 52 Week High | $88.16 | |||
| Open | $1194.01 | 52 Week Low | $67.88 | |||
| Day High | $1199.00 | P/E | 273.19 | |||
| Day Low | $1171.20 | EPS | $4.32 | |||
| Volume | 2,273,559 | |||||
